BioTech/Drugs - Austin, TX, us
QSAM Biosciences, Inc. is a clinical stage company developing next-generation nuclear medicines for the treatment of cancer. Our lead product, Samarium-153 DOTMP (CycloSam®), is an advanced therapeutic radiopharmaceutical for multiple indications: treatment of primary bone cancer and metastatic bone cancers from the breast, prostate and lungs; bone marrow ablation; and reduction in external radiation.
Outlook
Nginx
WordPress.org
Google Cloud Hosting
Shutterstock